1186426-66-3
Chemical Structure
DBPR108
- CAS No.: 1186426-66-3
- Formula:C16H25FN4O2
- Molecular Weight:324.39
IUPAC Name: (2S,4S)-4-fluoro-1-((2-methyl-4-oxo-4-(pyrrolidin-1-yl)butan-2-yl)glycyl)pyrrolidine-2-carbonitrile
InChIKey: VQKSCYBKUIDZEI-STQMWFEESA-N
SMILES: N#C[C@H]1N(C(CNC(C)(C)CC(N2CCCC2)=O)=O)C[C@@H](F)C1
Biological Activity: DBPR108 is an orally active, selective dipeptidyl peptidase-4 (DPP-4) inhibitor with an IC50 of 15 nM. DBPR108 reduces glycated hemoglobin, fasting plasma glucose and postprandial plasma glucose levels, increases serum active GLP-1 and insulin levels, and improves glucose tolerance. DBPR108 can be used in research related to type 2 diabetes[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DBPR108 | 99.93% | DBPR108 is an orally active, selective dipeptidyl peptidase-4 (DPP-4) inhibitor with an IC50 of 15 nM. DBPR108 reduces glycated hemoglobin, fasting plasma glucose and postprandial plasma glucose levels, increases serum active GLP-1 and insulin levels, and improves glucose tolerance. DBPR108 can be used in research related to type 2 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wang W, et al. Prusogliptin (DBPR108) monotherapy in treatment-naïve patients with type 2 diabetes: A randomized, double-blind, active and placebo-controlled, phase 3 study. Diabetes, obesity & metabolism. 2024 Apr;26(4):1321-1332.
- [2]. Yeh KC, et al. DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity. Life sciences. 2021 Aug 01;278:119574.
